Novartis reports further positive real-world data for its Leqvio (inclisiran) in the reduction of low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD).

According to the V-INITIATE trial, the early addition of Leqvio twice a year to maximum-tolerance statin therapy, prior to guideline-recommended ezetimibe, significantly reduced LDL-C in patients who had failed statin therapy.

The safety results were consistent with those of the pivotal Phase III clinical trial program and long-term open-label extension trials, ORION-3 and ORION-8, which demonstrated sustained safety for up to six years of treatment

The Swiss healthcare group points out that these latest data were presented at the American College of Cardiology's annual scientific session and published simultaneously in the Journal of the American College of Cardiology.

Copyright (c) 2024 CercleFinance.com. All rights reserved.